HC Wainwright Issues Pessimistic Forecast for MLTX Earnings

Key Points

• HC Wainwright revised its Q3 2025 EPS estimate for MoonLake Immunotherapeutics downward to ($0.96), reflecting a decrease from a prior estimate of ($0.79), alongside a full-year projection of ($1.79) EPS.
• The company recently reported Q2 earnings of ($0.87) EPS, missing estimates by $0.14 and showing a decline from ($0.39) EPS in the same quarter last year.
• Despite negative earnings forecasts, various analysts hold a consensus rating of "Moderate Buy," with an average price target of $74.43 for the stock.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) - Investment analysts at HC Wainwright dropped their Q3 2025 earnings per share estimates for shares of MoonLake Immunotherapeutics in a research note issued to investors on Monday, August 11th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($0.96) per share for the quarter, down from their previous forecast of ($0.79). The consensus estimate for MoonLake Immunotherapeutics' current full-year earnings is ($1.79) per share. HC Wainwright also issued estimates for MoonLake Immunotherapeutics' Q4 2025 earnings at ($0.89) EPS, FY2025 earnings at ($3.37) EPS, Q1 2026 earnings at ($0.80) EPS, Q2 2026 earnings at ($0.87) EPS, Q3 2026 earnings at ($0.95) EPS, Q4 2026 earnings at ($1.02) EPS and FY2026 earnings at ($3.64) EPS.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.73) by ($0.14). During the same period last year, the business earned ($0.39) earnings per share.

Several other brokerages also recently weighed in on MLTX. Rothschild & Co Redburn began coverage on shares of MoonLake Immunotherapeutics in a research note on Monday, July 28th. They issued a "neutral" rating and a $65.00 target price for the company. The Goldman Sachs Group boosted their target price on shares of MoonLake Immunotherapeutics from $74.00 to $82.00 and gave the company a "buy" rating in a research note on Wednesday, August 6th. Wolfe Research raised shares of MoonLake Immunotherapeutics from a "peer perform" rating to an "outperform" rating and set a $61.00 target price for the company in a research note on Monday, May 19th. Wedbush reissued an "outperform" rating and issued a $80.00 target price (up previously from $78.00) on shares of MoonLake Immunotherapeutics in a research note on Tuesday, May 13th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $66.00 target price on shares of MoonLake Immunotherapeutics in a research note on Tuesday, May 13th. Seven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to MarketBeat.com, MoonLake Immunotherapeutics has an average rating of "Moderate Buy" and an average target price of $74.43.

MoonLake Immunotherapeutics Price Performance

MLTX stock traded down $0.22 during trading on Thursday, hitting $53.51. The stock had a trading volume of 140,615 shares, compared to its average volume of 475,515. The company's 50 day moving average price is $49.74 and its two-hundred day moving average price is $43.47. MoonLake Immunotherapeutics has a 1-year low of $31.42 and a 1-year high of $58.26. The stock has a market cap of $3.44 billion, a price-to-earnings ratio of -19.19 and a beta of 1.27. The company has a debt-to-equity ratio of 0.21, a quick ratio of 16.65 and a current ratio of 16.65.

Institutional Trading of MoonLake Immunotherapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MLTX. LPL Financial LLC grew its holdings in MoonLake Immunotherapeutics by 19.5% in the 4th quarter. LPL Financial LLC now owns 8,146 shares of the company's stock valued at $441,000 after buying an additional 1,332 shares during the period. Geode Capital Management LLC grew its holdings in shares of MoonLake Immunotherapeutics by 0.9% during the 4th quarter. Geode Capital Management LLC now owns 58,950 shares of the company's stock worth $3,192,000 after purchasing an additional 540 shares during the period. Mariner LLC purchased a new stake in shares of MoonLake Immunotherapeutics during the 4th quarter worth about $272,000. PEAK6 LLC purchased a new stake in shares of MoonLake Immunotherapeutics during the 4th quarter worth about $271,000. Finally, Marshall Wace LLP grew its holdings in shares of MoonLake Immunotherapeutics by 7.9% during the 4th quarter. Marshall Wace LLP now owns 1,245,299 shares of the company's stock worth $67,433,000 after purchasing an additional 90,914 shares during the period. Hedge funds and other institutional investors own 93.85% of the company's stock.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.